Prulifloxacin

Prulifloxacin (NM441) is an orally active fluoroquinolone antibiotic with a broad spectrum of activity against Gram-positive and -negative bacteria. Prulifloxacin is a proagent of a thiazeto-quinoline carboxylic acid derivative Ulifloxacin (NM394) . Prulifloxacin has the potential for lower urinary tract infections and exacerbations of chronic bronchitis[1][2].

Product Specifications

CAS Number

[123447-62-1]

Product Name Alternative

NM441

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Prulifloxacin.html

Concentration

10mM

Purity

98.05

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=C(C1=C(SC2C)N2C3=C(C=C(F)C(N4CCN(CC5=C(C)OC(O5)=O)CC4)=C3)C1=O)O

Molecular Formula

C21H20FN3O6S

Molecular Weight

461.46

Precautions

H302, H315, H319, H335

References & Citations

[1]M Ozaki, et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother. 1991 Dec;35 (12) :2496-9.|[2]Guillem Prats, et al. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4 (1) :27-41.